KRAS and colorectal carcinoma: For example, in the analysis of KRAS, NRAS, and BRAF mutations in 850 colorectal cancer (CRC) cases, the concordance rate was 88.6%, accounting for all mutations including those not in the Idylla cartridge by design [32].